Pharma Mar, S.A. (LON:0RC6)

Market Cap	1.33B -0.0%
Revenue (ttm)	193.13M +26.6%
Net Income	65.42M +187.0%
EPS	3.75 +188.7%
Shares Out	n/a
PE Ratio	20.33
Forward PE	26.08
Dividend	0.68 (0.77%)
Ex-Dividend Date	Jun 25, 2025

Volume	2,063
Average Volume	3,412
Open	88.75
Previous Close	90.15
Day's Range	86.00 - 93.75
52-Week Range	65.05 - 102.30
Beta	0.45
RSI	62.51
Earnings Date	Apr 24, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 505
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RC6

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.

Financial numbers in EUR